Affordable Access

Publisher Website

Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis

Authors
Journal
Vaccine
0264-410X
Publisher
Elsevier
Publication Date
Volume
30
Issue
27
Identifiers
DOI: 10.1016/j.vaccine.2012.04.034
Keywords
  • Meningococcal
  • Serogroup C
  • Serogroup C Conjugate Vaccines
  • Immunization Schedules
  • Immunogenicity

Abstract

Abstract Background To assess antibody titers afforded by meningococcal C- (MenC) tetanus toxoid conjugate vaccine at 12 months of age in three different immunization schedules. Methods This prospective study included three similar cohorts of healthy infants from 1-dose, 2-dose and 3-dose MenC infant immunization programs. Infants were enrolled at 12 months of age and given the final scheduled dose of MenC-tetanus toxoid conjugate vaccine with sera collected prior to and 1 month after the vaccination. Serum bactericidal activity (SBA) titers≥1:8 were considered protective. Results Before the 12 month dose, participants had significantly different protective titers according to the number of prior doses received: 100% (95% CI 97.6–100%) of infants who had 2 prior doses (at 2 and 4 months) were protected compared to 84.0% (76.7–89.3%) of participants with one dose (at 2 months) and 27.6% (21.0–35.4%) of unvaccinated infants. All subjects were protected after the 12 month MenC dose, but titers were higher with prior priming. Conclusions Two MenC doses given in infancy afford optimal protection during the first year of life; however, substantial protection was seen after one dose at 2 months.

There are no comments yet on this publication. Be the first to share your thoughts.